David A Isenberg

Summary

Affiliation: University College London
Country: UK

Publications

  1. ncbi Elevated levels of the 90 kDa heat shock protein (hsp90) in SLE correlate with levels of IL-6 and autoantibodies to hsp90
    B J Ripley
    Institute of Child Health, University College London, UK
    J Autoimmun 17:341-6. 2001
  2. ncbi Rituximab-it was the best of times, it was the worst of times
    David A Isenberg
    University College London, United Kingdom
    Autoimmun Rev 11:790-1. 2012
  3. ncbi Meryl Streep and the problems of clinical trials
    David A Isenberg
    Centre for Rheumatology, Division of Medicine, University College London, The Rayne Building, 5 University Street, London WC1E 6JF, UK
    Arthritis Res Ther 14:113. 2012
  4. ncbi B cell depletion in autoimmune disease
    Claire Gorman
    Centre for Rheumatology, The Middlesex Hospital, University College London, UK
    Arthritis Res Ther 5:S17-21. 2003
  5. ncbi 52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block
    Christine Fritsch
    UPR 9021 Centre National de la Recherche Scientifique, Institut de Biologie Moleculaire et Cellulaire, Strasbourg, France
    Arthritis Res Ther 8:R4. 2006
  6. ncbi In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype
    Hector Chinoy
    Rheumatic Diseases Centre, Hope Hospital, Salford, UK
    Arthritis Res Ther 8:R13. 2006
  7. ncbi The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin
    Ian Giles
    Centre for Rheumatology, Department of Medicine, University College London, UK
    Arthritis Res Ther 7:R47-56. 2005
  8. ncbi Systemic Lupus International Collaborating Group--onwards and upwards?
    D Isenberg
    Centre for Rheumatology Research, UCL Division of Medicine, Room 331, 3rd Floor, The Windeyer Building, 46 Cleveland Street, London, W1T 4JF, UK
    Lupus 15:606-7. 2006
  9. ncbi Fifty years of anti-ds DNA antibodies: are we approaching journey's end?
    D A Isenberg
    Centre for Rheumatology Research, Division of Medicine, University College London, London W1T 4JF, UK
    Rheumatology (Oxford) 46:1052-6. 2007
  10. ncbi Thirty years, five hundred patients: some lessons learned from running a lupus clinic
    D Isenberg
    Centre for Rheumatology, UCL Division of Medicine, London, UK
    Lupus 19:667-74. 2010

Collaborators

Detail Information

Publications144 found, 100 shown here

  1. ncbi Elevated levels of the 90 kDa heat shock protein (hsp90) in SLE correlate with levels of IL-6 and autoantibodies to hsp90
    B J Ripley
    Institute of Child Health, University College London, UK
    J Autoimmun 17:341-6. 2001
    ..These results support a model in which elevated levels of IL-6 in SLE patients induce elevated levels of hsp90 protein which in turn results in the production of autoantibodies to this protein...
  2. ncbi Rituximab-it was the best of times, it was the worst of times
    David A Isenberg
    University College London, United Kingdom
    Autoimmun Rev 11:790-1. 2012
    ..Given the widespread use of BCD in SLE it seems likely that it will continue to be used though better designed trials (which work) would help resolve on-going problems with regulatory and funding agencies...
  3. ncbi Meryl Streep and the problems of clinical trials
    David A Isenberg
    Centre for Rheumatology, Division of Medicine, University College London, The Rayne Building, 5 University Street, London WC1E 6JF, UK
    Arthritis Res Ther 14:113. 2012
    ..The evidence clearly points to a previously unrecognised capacity for mycophenolate to cause notable drops in immunoglobulin levels as the prime suspect...
  4. ncbi B cell depletion in autoimmune disease
    Claire Gorman
    Centre for Rheumatology, The Middlesex Hospital, University College London, UK
    Arthritis Res Ther 5:S17-21. 2003
    ..The first autoimmune disease to be treated effectively was chronic idiopathic thrombocytopaenia. More recent success has been demonstrated in patients with rheumatoid arthritis and systemic lupus erythematosus...
  5. ncbi 52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block
    Christine Fritsch
    UPR 9021 Centre National de la Recherche Scientifique, Institut de Biologie Moleculaire et Cellulaire, Strasbourg, France
    Arthritis Res Ther 8:R4. 2006
    ..IgG antibodies to Ro52 peptides 1-13, 107-122, 277-292 and 365-382 may therefore represent important biomarkers to predict a complication in pregnant lupus women with Ro52 antibodies...
  6. ncbi In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype
    Hector Chinoy
    Rheumatic Diseases Centre, Hope Hospital, Salford, UK
    Arthritis Res Ther 8:R13. 2006
    ..In conclusion, these findings support the notion that myositis patients with differing myositis serology have different immunogenetic profiles, and that these profiles may define specific myositis subtypes...
  7. ncbi The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin
    Ian Giles
    Centre for Rheumatology, Department of Medicine, University College London, UK
    Arthritis Res Ther 7:R47-56. 2005
    ..Subsets of arginine residues at specific locations in the CDRs of heavy chains and light chains of pathogenic antiphospholipid antibodies are important in determining their ability to bind CL...
  8. ncbi Systemic Lupus International Collaborating Group--onwards and upwards?
    D Isenberg
    Centre for Rheumatology Research, UCL Division of Medicine, Room 331, 3rd Floor, The Windeyer Building, 46 Cleveland Street, London, W1T 4JF, UK
    Lupus 15:606-7. 2006
  9. ncbi Fifty years of anti-ds DNA antibodies: are we approaching journey's end?
    D A Isenberg
    Centre for Rheumatology Research, Division of Medicine, University College London, London W1T 4JF, UK
    Rheumatology (Oxford) 46:1052-6. 2007
    ....
  10. ncbi Thirty years, five hundred patients: some lessons learned from running a lupus clinic
    D Isenberg
    Centre for Rheumatology, UCL Division of Medicine, London, UK
    Lupus 19:667-74. 2010
    ..I have been involved with the clinic since July 1979 and in this article offer some thoughts about the complexities of managing systemic lupus erythematosus...
  11. ncbi BILAG, SLEDAI, SIS, ECLAM, WAM, SLAM .... thank you MAM
    D A Isenberg
    Centre for Rheumatology, University College, London W1T 4JF UK
    Lupus 16:849-51. 2007
  12. ncbi Biological treatments for systemic lupus erythematosus
    D Isenberg
    Scand J Rheumatol 31:187-91. 2002
    ..This review will focus on the biological therapies currently under investigation-with particular attention on the cytokine-directed therapies...
  13. ncbi International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease
    D A Isenberg
    Center for Rheumatology, Department of Medicine, The Middlesex Hospital, University College London, London, UK
    Rheumatology (Oxford) 43:49-54. 2004
    ..To devise new tools to assess activity and damage in patients with idiopathic myopathies (IIM)...
  14. ncbi Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems
    S M Sultan
    Centre for Rheumatology, Department of Medicine, University College Hospital, London W1P 9PG, UK
    Rheumatology (Oxford) 42:230-4. 2003
    ..We also sought to analyse the clinical and serological outcomes of patients with haemolytic anaemia and thrombocytopenia with systemic lupus erythematosus (SLE) as compared with patients without these cytopenias...
  15. ncbi Treating patients with lupus with B-cell depletion
    D A Isenberg
    Division of Medicine, Centre for Rheumatology, University College London, London, UK
    Lupus 17:400-4. 2008
    ..However, these studies have all been open label and the results of double blind controlled studies are eagerly awaited...
  16. ncbi Lupus nephritis: assessing the evidence, considering the future
    D Isenberg
    Department of Rheumatology, University College Hospital, London, UK
    Lupus 16:210-1. 2007
  17. ncbi The Systemic Lupus International Collaborating Clinics (SLICC) group - it was 20 years ago today
    D A Isenberg
    Centre for Rheumatology, UCL Division of Medicine, London, UK
    Lupus 20:1426-32. 2011
    ..This brief review traces the origins of the group focussing on its more recent history and reviewing some of its major contributions to lupus research during the past two decades...
  18. ncbi BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus
    D A Isenberg
    Centre for Rheumatology, University College London, 4th Floor, Arthur Stanley House, 40 50 Tottenham Street, London W1T 4NJ, UK
    Rheumatology (Oxford) 44:902-6. 2005
    ..To devise a more discriminating version of the British Isles Lupus Assessment Group (BILAG) disease activity index and to show that it is reliable...
  19. ncbi Anti-dsDNA antibodies: still a useful criterion for patients with systemic lupus erythematosus?
    D Isenberg
    Centre for Rheumatology, Department of Medicine, UCL London, UK
    Lupus 13:881-5. 2004
    ....
  20. ncbi B cell targeted therapies in autoimmune diseases
    David A Isenberg
    University College Hospital, Centre for Rheumatology, The Middlesex Hospital, London, United Kingdom
    J Rheumatol Suppl 77:24-8. 2006
    ..Although these studies contain small cohorts of patients, they demonstrate that B cell-modulating therapies show promise in treatment of a variety of autoimmune diseases...
  21. ncbi Systemic lupus erythematosus--2005 annus mirabilis?
    David Isenberg
    Center for Rheumatology, University College London Hospitals, London, UK
    Nat Clin Pract Rheumatol 2:145-52. 2006
    ..This wolf might not yet be about to become extinct but its survival is increasingly under threat!..
  22. ncbi An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA
    D A Isenberg
    Centre for Rheumatology, Division of Medicine, University College London, London, UK
    Ann Rheum Dis 70:54-9. 2011
    ....
  23. ncbi A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients
    Tim Y T Lu
    University College of London, London, UK
    Arthritis Rheum 61:482-7. 2009
    ....
  24. ncbi Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study
    Jessica J Manson
    Centre for Rheumatology Research, University College London, Windeyer Institute, 46 Cleveland Street, London W1T 4JF, UK
    Arthritis Res Ther 11:R154. 2009
    ..We assessed how well anti-alpha-actinin, anti-nucleosome and anti-double-stranded DNA (anti-dsDNA) antibodies reflected renal outcome measures in patients with new-onset LN followed for up to 2 years...
  25. ncbi Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus
    Sean G O'Neill
    University College London, London, UK
    Arthritis Rheum 62:845-54. 2010
    ..We undertook this study to examine whether levels of these antibodies rise in association with increased SLE disease activity...
  26. ncbi Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43
    Yiannis Ioannou
    University College London, London, UK
    Arthritis Rheum 56:280-90. 2007
    ..However, peptides homologous to other regions of domain I have also been shown to bind aPL. Furthermore, there are no published reports of the effects of altering R39, which has greater surface exposure than the G40-R43 residues...
  27. ncbi Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome
    Anastasia Lambrianides
    University College London, London, UK
    Arthritis Rheum 56:2392-401. 2007
    ..The present study was undertaken to investigate, using this expression system, the importance of the arginine residue at position 53 (R53) in B3 V(H)...
  28. ncbi Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity
    Lesley J Mason
    Centre for Rheumatology, Division of Medicine, University College London, UK
    Arthritis Res Ther 7:R971-83. 2005
    ..Sequence changes may alter the pathogenicity of B3, but further studies using different techniques are needed to investigate this possibility...
  29. ncbi A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli
    Yiannis Ioannou
    Centre for Rheumatology, Department of Medicine, University College London, Arthur Stanley House, 40 50 Tottenham Street, London, W1T 4NJ, UK
    BMC Biotechnol 6:8. 2006
    ..Expressing this protein in bacteria could facilitate studies investigating how this molecule interacts with aPL...
  30. ncbi Lupus autoantibodies to native DNA preferentially bind DNA presented on PolIV
    Sanjeev Kumar
    Centre for Rheumatology, Department of Medicine, University College London Hospital, London, UK
    Immunology 114:418-27. 2005
    ..This difference in binding ability may help to distinguish those dsDNA antibodies that are more pathogenic...
  31. ncbi Beta-2-glycoprotein specificity of human anti-phospholipid antibody resides on the light chain: a novel mechanism for acquisition of cross-reactivity by an autoantibody
    Sanjeev Kumar
    Department of Medicine, Centre for Rheumatology, Bloomsbury Rheumatology Unit, University College London Hospital, Arthur Stanley House, 40 50 Tottenham Street, London W1P 9PG, UK
    Mol Immunol 42:39-48. 2005
    ..The possible mechanisms that such antibodies may employ to recognise their antigens, are discussed...
  32. ncbi Fine binding characteristics of human autoantibodies-partial molecular characterization
    Sanjeev Kumar
    Bloomsbury Rheumatology Unit, Department of Medicine, Centre for Rheumatology, University College London W1P 9PG, UK
    Mol Immunol 41:495-510. 2004
    ..This observation may in some cases provide a mechanism for the common expression of a variety of autoantibodies observed in systemic lupus erythematosus (SLE)...
  33. ncbi CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients
    Paul A Blair
    Centre for Rheumatology Research, Department of Medicine, University College London, 46 Cleveland Street, London W1T4 JF, UK
    Immunity 32:129-40. 2010
    ..Altered cellular function within this compartment may impact effector immune responses in SLE and other autoimmune disorders...
  34. ncbi The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus
    J Tyrrell-Price
    Centre for Rheumatology Research, Immunology Department, University College London, UK
    Clin Exp Immunol 124:118-25. 2001
    ..06). Together these data suggest that the effect of these cytokines on antibody production by SLE PBMCs involves several factors; one of which is disease activity...
  35. ncbi Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus
    Elizabeth C Jury
    Department of Medicine, Centre for Rheumatology, University College London, London, UK
    Eur J Immunol 40:569-78. 2010
    ..Collectively our data identify CTLA-4 dysfunction as a potential cause for abnormal T-cell activation in patients with SLE, which could be targeted for therapy...
  36. ncbi Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells
    Anneleen Bosma
    Centre for Rheumatology Research, Division of Medicine, University College London, London WC1E 6JF, UK
    Immunity 36:477-90. 2012
    ..We propose that healthy B cells are pivotal for iNKT cell homeostasis...
  37. ncbi Interrater reliability and aspects of validity of the myositis damage index
    Shabina M Sultan
    University College London Hospitals, UK
    Ann Rheum Dis 70:1272-6. 2011
    ..To test the interrater reliability, internal consistency and aspects of validity of the myositis damage index (MDI) in the assessment of damage in adult patients with idiopathic inflammatory myopathy (IIM)...
  38. ncbi Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis?
    Lesley J Mason
    Department of Medicine, University College London, London, UK
    Arthritis Rheum 50:866-70. 2004
    ..Both human monoclonal anti-DNA antibodies and antibodies affinity purified from the sera of patients with systemic lupus erythematosus (SLE) were investigated...
  39. ncbi Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus
    Fabian Flores-Borja
    William Harvey Institute, Queen Mary School of Medicine and Dentistry, London, UK
    Arthritis Rheum 56:291-302. 2007
    ..The present study was undertaken to investigate the causes of this altered regulation of Lyn by assessing the expression levels of regulatory molecules and their translocation into the signaling domains of SLE B lymphocytes...
  40. ncbi Somatic mutations to arginine residues affect the binding of human monoclonal antibodies to DNA, histones, SmD and Ro antigen
    Joanna Haley
    Centre for Rheumatology/Bloomsbury Rheumatology Unit, Division of Medicine, University College, London, UK
    Mol Immunol 40:745-58. 2004
    ....
  41. ncbi B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response
    Kristine P Ng
    Centre for Rheumatology, University College London, London, UK
    Ann Rheum Dis 66:1259-62. 2007
    ..It was also determined whether baseline parameters can predict the likelihood of disease flare...
  42. ncbi Systemic lupus erythematosus
    Anisur Rahman
    Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom
    N Engl J Med 358:929-39. 2008
  43. ncbi An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study
    C T Ravirajan
    Centre for Rheumatology, Bloomsbury Rheumatology Unit, Department of Medicine, University College London, London W1T 4NJ, UK
    Rheumatology (Oxford) 40:1405-12. 2001
    ..There is a strong correlation between the level of anti-HS antibodies and disease activity in patients with lupus nephritis as measured by BILAG...
  44. ncbi Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody
    C T Ravirajan
    Centre for Rheumatology, Department of Medicine, University College London, Arthur Stanley House, London W1T 4NJ, UK
    Rheumatology (Oxford) 43:442-7. 2004
    ....
  45. ncbi The BILAG-2004 systems tally--a novel way of representing the BILAG-2004 index scores longitudinally
    Chee Seng Yee
    Department of Rheumatology, Doncaster Royal Infirmary, Armthorpe Road, Doncaster DN2 5LT, UK
    Rheumatology (Oxford) 51:2099-105. 2012
    ..This was an exploratory analysis to develop a new way of representing BILAG-2004 system scores longitudinally that would be clinically meaningful and easier to analyse in comparison with multiple categorical variables...
  46. ncbi A negatively charged domain of LAT mediates its interaction with the active form of Lck
    Panagiotis S Kabouridis
    William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, UK
    Mol Membr Biol 28:487-94. 2011
    ..Therefore, in addition to the conserved tyrosines, the 112-126 domain identified here could be important for certain functions of LAT in T cells...
  47. ncbi Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus
    Fabian Flores-Borja
    William Harvey Institute, Queen Mary School of Medicine and Dentistry, London, UK
    Arthritis Rheum 52:3955-65. 2005
    ..In this study, we determined the level and subcellular distribution of Lyn protein, a key negative regulator of B cell receptor signaling, and assessed whether altered Lyn expression is characteristic of B cells in the setting of SLE...
  48. ncbi Protein phosphorylation and kinome profiling reveal altered regulation of multiple signaling pathways in B lymphocytes from patients with systemic lupus erythematosus
    Taher E Taher
    Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    Arthritis Rheum 62:2412-23. 2010
    ..The present study was undertaken to examine the extent of signaling abnormalities that relate to altered B cell responses in SLE...
  49. ncbi Relative importance of different human aPL derived heavy and light chains in the binding of aPL to cardiolipin
    Ian P Giles
    Department of Medicine, Centre for Rheumatology, University College London, Arthur Stanley House, 40 50 Tottenham Street, London W1T 4NJ, UK
    Mol Immunol 40:49-60. 2003
    ....
  50. ncbi Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways
    Anastasia Lambrianides
    Medical Molecular Biology Unit, Institute of Child Health, Department of Medicine, Centre for Rheumatology Research, University College London, London, UK
    J Immunol 184:6622-8. 2010
    ....
  51. ncbi Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen
    Amara N Ezeonyeji
    Department of Rheumatology, University College London Hospital, London NW1 2PG, UK
    Rheumatology (Oxford) 51:476-81. 2012
    ..To assess the effectiveness of B-cell depletion therapy (BCDT) as a steroid-sparing treatment in newly diagnosed SLE patients...
  52. ncbi The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation
    Tabitha Turner-Stokes
    Centre for Rheumatology Research, University College Hospital, London, UK
    Rheumatology (Oxford) 50:1401-8. 2011
    ..The aims of the study were to: (i) assess the efficacy and safety of repeated cycles of BCDT in treating refractory SLE; and (ii) assess whether retreatment produced a more sustained clinical response...
  53. ncbi Repeated B cell depletion in treatment of refractory systemic lupus erythematosus
    K P Ng
    Centre for Rheumatology, University College London, Arthur Stanley House, 40-50 Tottenham Street, London W1T 4NJ, UK
    Ann Rheum Dis 65:942-5. 2006
    ..The median duration of clinical benefit was 12 months. Most patients tolerate re-treatment very well. CONCLUSION: Re-treatment with B cell depletion of patients with severe SLE is safe and may be effective for 6-12 months on average...
  54. ncbi Expression of the Fabs of human auto-antibodies in Escherichia coli: optimization and determination of their fine binding characteristics and cross-reactivity
    S Kumar
    Centre for Rheumatology, and Department of Biochemistry and Molecular Biology, University College London, UK
    J Mol Biol 308:527-39. 2001
    ..Such auto- antigen specificity and/or cross-reactivity may dictate the potential of an auto-antibody to cause pathogenicity and may provide an explanation as to why apparently similar auto-antibodies behave differently in vivo...
  55. ncbi Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus
    Elizabeth C Jury
    Centre for Rheumatology, Royal Free and University College Medical School, University College London, London, United Kingdom
    J Clin Invest 113:1176-87. 2004
    ....
  56. ncbi p185, an immunodominant epitope, is an autoantigen mimotope
    Sanjeev Kumar
    Centre for Rheumatology, University College London Division of Medicine, University College London Hospital, London W1T 4JF, UK
    J Biol Chem 286:26220-7. 2011
    ..This is the first demonstration of a naturally occurring autoantigen mimotope. The present study identifies a potential antigenic stimulus that might trigger systemic lupus erythematosus in a subset of patients...
  57. ncbi Agrin signalling contributes to cell activation and is overexpressed in T lymphocytes from lupus patients
    Elizabeth C Jury
    Centre for Rheumatology, Royal Free and University College Medical School, University College London, London, UK
    J Immunol 179:7975-83. 2007
    ..These results demonstrate that agrin expression in human T cells is regulated by cell activation and IFN-alpha, and may have an important function during cell activation with potential implications for autoimmunity...
  58. ncbi Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice
    Paul A Blair
    Department of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom
    J Immunol 182:3492-502. 2009
    ..Taken together, our results suggest a novel cellular approach for the amelioration of experimental lupus...
  59. ncbi Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus
    Sean G O'Neill
    Centre for Rheumatology Research, Division of Medicine, University College London, London, UK
    Rheumatology (Oxford) 48:573-5. 2009
    ..To develop a strategy for stratifying risk of cardiovascular disease (CVD) in a cohort of patients with SLE and to test the usefulness of this strategy in rationalizing management of cardiovascular risk factors...
  60. ncbi Familial clustering of non-nuclear autoantibodies and C3 and C4 complement components in systemic lupus erythematosus
    Saowalak Hunnangkul
    London School of Hygiene and Tropical Medicine, London, UK
    Arthritis Rheum 58:1116-24. 2008
    ..In addition, we examined relationships between anti-C1q and C3 and C4 levels...
  61. ncbi Antiphospholipid antibodies are induced by in vitro fertilization and correlate with paraoxonase activity and total antioxidant capacity of plasma in infertile women
    J Delgado Alves
    Centre for Rheumatology, Department of Medicine, Univ College London, UK
    Lupus 14:373-80. 2005
    ..In conclusion PON activity is decreased in women submitted to IVF treatment and is associated with the presence of antiphospholipid antibodies. These factors might contribute to the increased oxidative status found in these patients...
  62. ncbi A human anti-dsDNA monoclonal antibody caused hyaline thrombi formation in kidneys of 'leaky' SCID mice
    L J Mason
    Centre for Rheumatology/Bloomsbury Rheumatology Unit, Department of Medicine, University College London, London, UK
    Clin Exp Immunol 126:137-42. 2001
    ....
  63. ncbi Endothelial microparticle release is stimulated in vitro by purified IgG from patients with the antiphospholipid syndrome
    Charis Pericleous
    Centre for Rheumatology, Division of Medicine University College London, Rayne Institute, 4 th Floor, Room 422, 5 University Street, London
    Thromb Haemost 109:72-8. 2013
    ..3.4% ± 2.0 for HC IgG, p=0.0172). This study therefore demonstrates that purified polyclonal APS-IgG can drive EMP release. We propose that EMP generation may be a useful measure of aPL-mediated pathogenic effects upon EC...
  64. ncbi B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels
    Mark N Lazarus
    Centre for Rheumatology, University College London, 5 University Street, London WC1E 6JF, UK
    Rheumatology (Oxford) 51:1208-15. 2012
    ..To correlate the kinetics of B-cell repopulation with relapse after B-cell depletion therapy in SLE patients and address whether variation in relapse rate, B-cell numbers and phenotype are related to anti-dsDNA antibody levels...
  65. ncbi Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort
    Rekha Lopez
    Centre for Rheumatology, UCL Division of Medicine, London W1T 4JF, UK
    Rheumatology (Oxford) 51:491-8. 2012
    ..To estimate the effect of SLE disease activity, observed over a 12-month period, on the risk of irreversible organ damage and mortality, adjusted for potential confounding factors...
  66. ncbi Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy
    Michael R Ehrenstein
    Dept of Medicine, Centre for Rheumatology, Windeyer Institute, University College London, London W1T 4JF, England, UK
    J Exp Med 200:277-85. 2004
    ....
  67. ncbi Anti-cardiolipin/beta-2 glycoprotein activities co-exist on human anti-DNA antibody light chains
    Sanjeev Kumar
    Bloomsbury Rheumatology Unit, Department of Medicine, Centre for Rheumatology, University College London Hospital, Arthur Stanley House, 40 50 Tottenham Street, London W1P 9PG, UK
    Mol Immunol 40:517-30. 2003
    ..Computer-generated models of the three-dimensional structures of the auto-antibodies and their hybrids, suggest predominant interaction of their light chains with domain IV of beta2-GPI...
  68. ncbi Natural killer T cells in families of patients with systemic lupus erythematosus: their possible role in regulation of IGG production
    Matthew R J Green
    Imperial College School of Medicine, London, UK
    Arthritis Rheum 56:303-10. 2007
    ..To determine whether there is a link between the frequency of natural killer T (NKT) cells and high levels of IgG in patients with systemic lupus erythematosus (SLE) and their relatives...
  69. ncbi Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study
    Rupa Bessant
    University College London, London, UK
    Arthritis Rheum 55:892-9. 2006
    ..CONCLUSION: We identified significantly increased prevalence of some conventional and lupus-specific risk factors in patients with SLE immediately before a CVD event compared with controls matched for age or disease duration...
  70. ncbi mAbs in nonlupus autoimmune rheumatic disease
    Bryan R Whelan
    Department of Medicine, Centre for Rheumatology, University College London, London, UK
    Curr Opin Hematol 16:280-4. 2009
    ..We have summarized the evidence that does exist to support the use of mAb therapies in these diseases...
  71. ncbi British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus
    Chee Seng Yee
    Department of Rheumatology, Division of Infection and Immunity, Medical School, University of Birmingham, Birmingham, UK
    Arthritis Rheum 56:4113-9. 2007
    ..To determine the construct and criterion validity of the British Isles Lupus Assessment Group 2004 (BILAG-2004) index for assessing disease activity in systemic lupus erythematosus (SLE)...
  72. ncbi Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus
    Elizabeth C Jury
    Department of Medicine, Centre for Rheumatology, University College London, United Kingdom
    J Immunol 177:7416-22. 2006
    ..These findings demonstrate the potential for atorvastatin to target lipid raft-associated signaling abnormalities in autoreactive T cells and provide a rationale for its use in therapy of autoimmune disease...
  73. ncbi How do antiphospholipid antibodies bind beta2-glycoprotein I?
    Ian P Giles
    Centre for Rheumatology, University College London, 4th Floor Arthur Stanley House, 40 50 Tottenham Street, London W1T 4NJ, UK
    Arthritis Rheum 48:2111-21. 2003
  74. ncbi Antibodies to mannose binding lectin in patients with systemic lupus erythematosus
    M Y Mok
    Department of Immunology and Molecular Pathology and Rheumatology, Royal Free and University College Medical School, London, UK
    Lupus 13:522-8. 2004
    ..Thus the production of anti-MBL antibodies is likely to be a specific antigen-driven process. Its role in lupus pathogenesis remains to be elucidated...
  75. ncbi A comparison of autoimmune liver disease in juvenile and adult populations with systemic lupus erythematosus-a retrospective review of cases
    K S Irving
    Centre for Rheumatology, University College London Hospitals, London NW1 2PG, UK
    Rheumatology (Oxford) 46:1171-3. 2007
    ..To compare the prevalence and type of autoimmune liver disease in adult and juvenile patients with systemic lupus erythematosus (SLE) in a large UK cohort...
  76. ncbi B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients
    M J Leandro
    Centre for Rheumatology, University College London, London, UK
    Rheumatology (Oxford) 44:1542-5. 2005
    ..Our data provide strong support for the performance of a full double-blind control trial...
  77. ncbi An open study of B lymphocyte depletion in systemic lupus erythematosus
    Maria J Leandro
    Rheumatology, Middlesex Hospital, University College, 4th Floor Arthur Stanley House, 40 50 Tottenham Street, London W1T 4NJ, UK
    Arthritis Rheum 46:2673-7. 2002
    ..To gain preliminary evidence for the safety and efficacy of B lymphocyte depletion therapy in refractory systemic lupus erythematosus (SLE)...
  78. ncbi Inflammatory muscle disease assessment
    Tim Y T Lu
    Centre for Rheumatology, Room 331, 3rd Floor, Windeyer Building, University College London, 46 Cleveland Street, London W1T4JF, United Kingdom
    Curr Rheumatol Rep 10:328-32. 2008
    ....
  79. ncbi The origin and pathogenic consequences of anti-dsDNA antibodies in systemic lupus erythematosus
    Jessica J Manson
    Clinical Research Fellow, Centre for Rheumatology Research, University College London, UK
    Expert Rev Clin Immunol 2:377-85. 2006
    ..Identifying these pathogenic antibodies may well hold the key to the development of new, targeted therapies...
  80. ncbi B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles
    G Cambridge
    University College London, Centre for Rheumatology Research, Division of Medicine, Room 118 Windeyer Building, 46 Cleveland Street, London W1T 4JF, UK
    Arthritis Rheum 54:3612-22. 2006
    ..Clinical responses to B cell depletion therapy (BCDT), based on rituximab, are encouraging. Therefore, we undertook this study to investigate the effect of BCDT on antibody profiles...
  81. ncbi Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome
    J Delgado Alves
    Centre for Rheumatology, Department of Medicine, University College London, London, UK
    Rheumatology (Oxford) 42:893-9. 2003
    ..We studied the presence and patterns of cross-reactivity between antibodies directed against cardiolipin, high-density lipoprotein (HDL) and apolipoprotein A-I (Apo A-I) in patients with SLE and APS...
  82. ncbi In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept
    Y Ioannou
    Centre for Rheumatology Research, Windeyer Building, University College London, London, UK
    J Thromb Haemost 7:833-42. 2009
    ..Hence, we hypothesized that DI and DI(D8S/D9G) would inhibit aPL-induced pathogenicity in vivo...
  83. ncbi Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia
    B J M Ripley
    Institute of Child Health, 30 Guildford Street, London WC1N 1EH, UK
    Ann Rheum Dis 64:849-53. 2005
    ..Raised levels of the cytokines interleukin (IL) 6 and IL10 have been reported in patients with systemic lupus erythematosus (SLE)...
  84. ncbi B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres
    Y Ioannou
    Centre for Rheumatology, Department of Medicine, University College London, 250 Euston Road, London NW1 2PG, UK
    Ann Rheum Dis 67:425-6. 2008
    ....
  85. ncbi B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response
    G Cambridge
    Centre for Rheumatology Research, Department of Medicine, 46 Cleveland St, London W1T 4JF, UK
    Ann Rheum Dis 67:1011-6. 2008
    ..To assess the relationships between serum B lymphocyte stimulator (BLyS) levels, autoantibody profile and clinical response in patients with systemic lupus erythematosus (SLE) following rituximab-based B cell depletion therapy (BCDT)...
  86. ncbi Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis
    C T Ravirajan
    Department of Medicine, University College London, GB
    Eur J Immunol 28:339-50. 1998
    ..In this study we have shown for the first time using electron microscopy that a human IgG anti-dsDNA mAb, RH-14, is nephritogenic and that deposition of such an antibody alone is sufficient to induce renal damage...
  87. ncbi Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome
    J Delgado Alves
    Windeyer Institute of Medical Sciences, Room 118 Centre for Rheumatology, University College of London, 46 Cleveland Street, London W1T 4JF, UK
    Arthritis Rheum 46:2686-94. 2002
    ....
  88. ncbi Tumour necrosis factor alpha in systemic lupus erythematosus and anti-DNA autoantibody production
    R A Mageed
    Department of Immunology and Molecular Pathology, Royal Free and University College London, The Windeyer Institute, London, UK
    Lupus 11:850-5. 2002
    ..Further, we discuss recent data on the likely effects of blocking TNFalpha on anti-DNA autoantibody production...
  89. ncbi Counter-proliferative effects of nucleosomal antigens in cultures from lupus patients
    M R Salaman
    Department of Immunology, Imperial College School of Medicine St Mary's, London, UK
    Lupus 10:332-9. 2001
    ..If T cell sensitisation to histones is an important factor in the development of lupus, the disease may be preventable in those at risk by inducing tolerance to the appropriate peptides...
  90. ncbi A statistical analysis of the interrelationships between disease activity in different systems in systemic lupus erythematosus
    E Allen
    Department of Statistical Science, University College, London, UK
    Rheumatology (Oxford) 45:308-13. 2006
    ....
  91. ncbi Characterization of CD3+ CD4- CD8- (double negative) T cells in patients with systemic lupus erythematosus: production of IL-4
    G S Dean
    Department of Immunology and Molecular Pathology, Royal Free and University College School of Medicine, London, UK
    Lupus 11:501-7. 2002
    ....
  92. ncbi Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus
    R Bessant
    Centre for Rheumatology, University College London Hospitals, Arthur Stanley House, Tottenham Street, London W1T 4NJ, UK
    Rheumatology (Oxford) 43:924-9. 2004
    ..Patients with systemic lupus erythematosus (SLE) are at increased risk of myocardial infarction and stroke. We sought to determine how much of this risk was dependent on recognized cardiovascular risk factors...
  93. ncbi Serendipitous evidence of T lymphocyte activation in close female relatives of patients with systemic lupus erythematosus
    M R J Green
    Department of Immunology, Imperial College School of Medicine, London, UK
    Clin Exp Immunol 157:35-9. 2009
    ....
  94. ncbi Detection of anticardiolipin antibodies in culture supernatants
    G S Dean
    Department of Immunology, University College London Medical School, London, UK
    Clin Exp Rheumatol 19:251-7. 2001
    ....
  95. ncbi The importance of somatic mutations in the V(lambda) gene 2a2 in human monoclonal anti-DNA antibodies
    A Rahman
    Center for Rheumatology Bloomsbury Rheumatology Unit, Division of Medicine, University College, London, UK
    J Mol Biol 307:149-60. 2001
    ..In a third light chain, however, mutation to arginine at a different site blocked binding to DNA...
  96. ncbi Conversion of discoid lupus to antiphospholipid syndrome and SLE
    Michelle M A Fernando
    Section of Molecular Genetics and Rheumatology, Faculty of Medicine, Imperial College, London, UK
    Nat Clin Pract Rheumatol 4:106-10. 2008
    ..After admission to hospital, he developed autoimmune hemolytic anemia, thrombocytopenia, severe hypertension, proteinuria and a fluctuating level of consciousness...
  97. ncbi Syndromes and complications of interferon therapy
    Frances A Y Borg
    Department of Rheumatology, University College London Hospital, UK
    Curr Opin Rheumatol 19:61-6. 2007
    ..They are integral players in immunity and a number of immune-mediated complications can arise during interferon therapy. We have reviewed the occurrence of these complications, and the mechanisms behind them...
  98. ncbi Impaired C3b/iC3b deposition on Streptococcus pneumoniae in serum from patients with systemic lupus erythematosus
    Fiona Goldblatt
    Department of Medicine, Centre for Rheumatology, University College London Hospital, Rayne Institute, London, UK
    Rheumatology (Oxford) 48:1498-501. 2009
    ..To determine whether opsonization of Streptococcus pneumoniae with C3b/iC3b is impaired in serum from patients with SLE...
  99. ncbi Crossreactivity of human anti-dsDNA antibodies to phosphorylcholine: clues to their origin
    A Sharma
    Bloomsbury Rheumatology Unit/Centre for Rheumatology, Dept of Medicine, University College London, Arthur Stanley House, London, W1P 9PG, UK
    J Autoimmun 16:479-84. 2001
    ..The studies suggest there may be a T dependent and T independent response to DNA with the T dependent response displaying more crossreactivity with microbial antigen...
  100. ncbi Molecular cloning and expression of the Fabs of human autoantibodies in Escherichia coli. Determination of the heavy or light chain contribution to the anti-DNA/-cardiolipin activity of the Fab
    S Kumar
    Centre for Rheumatology, Bloomsbury Rheumatology Unit, the Department of Medicine and the Department of Biochemistry and Molecular Biology, University College London, London W1P 9PG, UK
    J Biol Chem 275:35129-36. 2000
    ..However, a compatible partner chain is necessary for optimum antigen binding activity of the antibody...
  101. ncbi Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus
    K P Ng
    University College London, London, UK
    Arthritis Rheum 55:900-4. 2006
    ..The majority of these patients experience a flare in the next 5 years and close followup is recommended. Anti-NCS antibodies may be a better predictor than anti-dsDNA antibodies for future flares...